CD16+ monocytes in predicting response to intranasal immunotherapy in patients with cerebrovascular pathology

Authors

  • E. Ya. Shevela Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
  • A. A. Ostanin Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
  • M. A. Tikhonova Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
  • M. N. Davydova Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
  • I. V. Meledina Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation
  • E. R. Chernykh Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russian Federation

DOI:

https://doi.org/10.25557/2310-0435.2022.03.145-146

Keywords:

Neuroimmunopathology

Abstract

Conference abstract

Downloads

Published

2022-10-15

Issue

Vol. 20 No. 3 (2022): Pathogenesis

Section

Brief reports

How to Cite

1.
Shevela EY, Ostanin AA, Tikhonova MA, Davydova MN, Meledina IV, Chernykh ER. CD16+ monocytes in predicting response to intranasal immunotherapy in patients with cerebrovascular pathology. Патогенез. 2022;20(3):145-146. doi:10.25557/2310-0435.2022.03.145-146